From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Corticosterone (17-Deoxycortisol) is an orally active and adrenal cortex-produced glucocorticoid, which plays an important role in regulating neuronal functions of the limbic system (including hippocampus, prefrontal cortex, and amygdala). Corticosterone increases the Rab-mediated AMPAR membrane traffic via SGK-induced phosphorylation of GDI. Corticosterone also interferes with the maturation of dendritic cells and shows a good immunosuppressive effect.
For research use only. We do not sell to patients.
Corticosterone (CORT) (10 µM, 24 h) is used to produce a cell stress model on the primary culture hippocampal neurons from rats. The decreased NHE1 expression levels in primary cell culture induced by CORT treatment are not affected by chloroquine (Fig. D) but significantly reversed with MG132 pretreatment (Fig. E).
Corticosterone (17-Deoxycortisol) is an orally active and adrenal cortex-produced glucocorticoid, which plays an important role in regulating neuronal functions of the limbic system (including hippocampus, prefrontal cortex, and amygdala). Corticosterone increases the Rab-mediated AMPAR membrane traffic via SGK-induced phosphorylation of GDI. Corticosterone also interferes with the maturation of dendritic cells and shows a good immunosuppressive effect[1][2][3][4].
IC50 & Target
Human Endogenous Metabolite
In Vitro
Corticosterone (100 nM; 30 min) via SGK phosphorylation of GDI at Ser-213, increases the formation of GDI-Rab4 complex, facilitating the functional cycle of Rab4 and Rab4-mediated recycling of AMPARs to the synaptic membrane[1].
Corticosterone (CORT) (1 µM; 48 h) shows good immunosuppressive properties (functionally compromises maturation of BMDC), which impairs LPS-induced up-regulation of maturation-associated markers (MHC class II, B7.2, B7.1 and CD40)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Caused a significant enhancement of mEPSC amplitude (mEPSC represents the postsynaptic response to release of individual vesicles of glutamate).
Increased the transmission of glutamatergic, and increased synaptic AMPAR currents via a Rab4-dependent mechanism.
Profoundly increased surface GluR1 cluster density, cluster size and cluster fluorescence intensity.
Significantly increased the amount of Rab4 that binded to WT-GDI, S45A-GDI, or S121A-GDI but not S213A-GDI.
Induced the phosphorylation of GST-WTGDI, GST-S45AGDI, and GST-S121AGDI, but not GST-S213AGDI, and this effect was blocked in cells transfected with SGK1 small interfering RNA.
Increased AMPAR surface expression via a mechanism dependent on GDI phosphorylation.
Completely blocked the expression of MHC class II and B7.2 that induced by LPS, and maximally impaired BMDC cells maturation at 12 h.
Reduced B7.1 by 50%, and slightly down-regulated CD40.
In Vivo
Corticosterone results in a marked reduction in the ability of BMDC cells to prime naive CD8+ T cells in vivo[2].
Corticosterone (0.03 or 1 mg/kg; s.c.; single) downregulates expression of BDNF mRNA in dentate gyrus and CA1 of rats[3].
Corticosterone (2.6 mg/kg; in animal feedings; 8 days) restores ethanol intake and preference to approximately normal preoperative levels in adrenalectomy (ADX) rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Adult male Wistar rats (150-170 g; adrenalectomized)[3].
Dosage:
0.03 or 1 mg/kg
Administration:
Subcutaneous injection; single.
Result:
Decreased expression of BDNF mRNA in dentate gyrus, with 25% and 50% lower for dosages of 0.03 and 1 mg/kg, respectively (3 h after administration).
Reduced approximately 40% BDNF mRNA level as compared to the t=0 h control group (3 h after administration), but the level increased by 100% when 12 h after administration (compared to t=3 h and t=6 h group).
Animal Model:
Male Wistar rats (3-week-old; adrenalectomized)[4].
Dosage:
2.6 mg/kg
Administration:
In animal feedings; 8 days.
Result:
Restored ethanol intake and preference of adrenalectomy (ADX) rats to approximately normal preoperative levels and to the levels observed in the sham-operated group (SH) rats.
Room temperature in continental US; may vary elsewhere.
Storage
Powder
-20°C
3 years
4°C
2 years
In solvent
-80°C
1 year
-20°C
6 months
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (288.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 14.29 mg/mL (41.25 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Preparing Stock Solutions
ConcentrationSolventMass
1 mg
5 mg
10 mg
1 mM
2.8863 mL
14.4317 mL
28.8634 mL
5 mM
0.5773 mL
2.8863 mL
5.7727 mL
10 mM
0.2886 mL
1.4432 mL
2.8863 mL
View the Complete Stock Solution Preparation Table
*Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day. The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μLDMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μLDMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3
Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μLDMSO stock solution (25.0 mg/mL) to 900 μLCorn oil, and mix evenly.
Protocol 4
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
This protocol yields a clear solution of ≥ 1.43 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (14.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 5
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
This protocol yields a clear solution of ≥ 1.43 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (14.3 mg/mL) to 900 μLCorn oil, and mix evenly.
For the following dissolution methods, please prepare the working solution directly.
It is recommended to prepare fresh solutions and use them promptly within a short period of time. The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution.
If precipitation or phase separation occurs during preparation,
heat and/or sonication can be used to aid dissolution.
Protocol 1
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 2 mg/mL (5.77 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C
Protocol 2
Add each solvent one by one: 20% HP-β-CD in Saline
Solubility: 4 mg/mL (11.55 mM); Suspended solution; Need ultrasonic
Solubility: 5 mg/mL (14.43 mM); Clear solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage
mg/kg
Animal weight (per animal)
g
Dosing volume (per animal)
μL
Number of animals
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO+
%
+
%
Tween-80
+
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO,
. All of co-solvents are available by MedChemExpress (MCE).
, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
*Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Powered by Bioz
